A Phase 1 interventional study of GLPG0634 100mg capsule once a day for 10 days in Healthy, sponsored by Galapagos NV. Completed at 1 site in Belgium. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-03-28.
Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of the study is to evaluate the amount of compound present in the blood (pharmacokinetics) after single and of multiple doses of GLPG0634 in elderly healthy subjects.
During the course of the study, the effect of aging on the pharmacokinetics as well as the effects of GLPG0634 on mechanism of action-related parameters in the blood (pharmacodynamics) will be assessed and the safety of multiple oral doses of GLPG0634 in elderly healthy subjects will be characterized.
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 40 and 50 years old
Drug: GLPG0634 100mg capsule once a day for 10 days
GLPG0634 100mg capsule once a day for 10 days in healthy subjects between 65 and 74 years old
Drug: GLPG0634 100mg capsule once a day for 10 days
GLPG0634 100mg capsule once a day for 10 days in healthy subjects of 75 years and older
Drug: GLPG0634 100mg capsule once a day for 10 days
The amount of GLPG0634 in plasma over time after single and multiple doses of GLPG0634
To characterize the amount of GLPG0634 in plasma over time - pharmacokinetics (PK) - after single and multiple oral doses in different age groups, including elderly healthy subjects, thereby assessing the effect of aging
Time frame: From predose (before first study drug administration) up to 72 hours post last study drug administration
The amount of GLPG0634 mechanism-of-action-related biomarkers in blood after multiple doses of GLPG0634
To characterize the effects of GLPG0634 on mechanism of action-related biomarkers in the blood over time - pharmacodynamics (PD) - after multiple oral doses in different age groups, including elderly healthy subjects, thereby assessing the effect of aging
Time frame: From predose (before first study drug administration) up to 24 hours post last study drug administration
Number of adverse events
To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of the number of adverse events reported
Time frame: From screening up to 10 days after the last study drug administration
Changes in vital signs as measured by heart rate, blood pressure and body temperature
To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in vital signs as measured by heart rate, blood pressure and body temperature reported
Time frame: From screening up to 10 days after the last study drug administration
Changes in 12-lead ECG measures
To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in 12-ECG measures reported
Time frame: From screening up to 10 days after the last study drug administration
Changes in physical exam measures
To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in physical examination reported
Time frame: From screening up to 10 days after the last study drug administration
Changes in blood safety lab parameters
To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in blood safety lab parameters assessed
Time frame: From screening up to 10 days after the last study drug administration
Changes in urine safety lab parameters
To evaluate the safety of multiple oral doses of GLPG0634 in healthy subjects of different age groups, including elderly, in terms of changes in urine safety lab parameters assessed
Time frame: From screening up to 10 days after the last study drug administration
The record gives a start of Jul 2012, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634